Neuropediatrics 2021; 52(06): 475-479
DOI: 10.1055/s-0040-1722680
Short Communication

Variable Genotype–Phenotype Correlation of Pompe's Disease Caused by a c.2015 G > A (p.Arg672Gln) Mutation in the GAA Gene

1   Pediatric Neurology Unit, Dana-Dwek Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel
2   Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Liora Sagi
1   Pediatric Neurology Unit, Dana-Dwek Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel
2   Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Deeksha Sarihyan Bali
3   Department of Pediatrics, Duke Medicine, Durham, North Carolina, United States
,
Catherine Rehder
4   Molecular Diagnostics Laboratory, Duke University Health System, Durham, North Carolina, United States
,
Rotem Orbach
1   Pediatric Neurology Unit, Dana-Dwek Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel
2   Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Aviva Fattal-Valevski
1   Pediatric Neurology Unit, Dana-Dwek Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel
2   Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
› Author Affiliations

Abstract

Pompe's disease occurs due to an autosomal recessive trait resulting from numerous distinctive mutations in the GAA gene. It manifests as a broad spectrum of clinical phenotypes with progressive weakness that impairs motor and respiratory functions being common for all its forms. Cardiac hypertrophy is a prominent feature of its classic infantile form. To date, the pathogenic variant c.2015G > A (p.Arg672Gln) in exon 14 of the GAA gene has been described in 10 children of different ethnic groups, with variable phenotypic presentations. This work describes three children from two unrelated families of Arab ethnicity who presented with infantile-onset Pompe's disease as a result of a c.2015G > A (p.Arg672Gln) mutation. The clinical course of the children we report was more severe than previous reports. This further emphasizes the lack of a strict genotype–phenotype correlation in regard to the unique c.2015G > A (p.R672Q) mutation that causes Pompe's disease. This information contributes to the knowledge of the phenotypic expression of the specific mutation c.2015G > A (p.Arg672Gln) that causes Pompe's disease.

Declaration of Patient Consent

The authors certify that they have obtained signed consent forms from the legal guardians of the patients presented in this report, who have agreed for the clinical information of the patients to be published. The patient's guardians understand that while the names and initials of the patients will not be published and that all efforts will be made to conceal their identity; their anonymity cannot be guaranteed.


Ethical Publication

We confirm that we have read the journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.




Publication History

Received: 16 July 2020

Accepted: 01 November 2020

Article published online:
12 February 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 U.S. National Library of Medicine. Genetics Home Reference. Published 2018. Accessed July 2020 at: https://ghr.nlm.nih.gov/
  • 2 Reuser AJJ, van der Ploeg AT, Chien YH. et al; On Behalf Of The Pompe Registry Sites. GAA variants and phenotypes among 1,079 patients with Pompe disease: data from the Pompe Registry. Hum Mutat 2019; 40 (11) 2146-2164
  • 3 van den Hout HM, Hop W, van Diggelen OP. et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003; 112 (02) 332-340
  • 4 Huie ML, Tsujino S, Sklower Brooks S. et al. Glycogen storage disease type II: identification of four novel missense mutations (D645N, G648S, R672W, R672Q) and two insertions/deletions in the acid alpha-glucosidase locus of patients of differing phenotype. Biochem Biophys Res Commun 1998; 244 (03) 921-927
  • 5 Luo JH, Qiu WJ, Fang D. et al. [Clinical and gene mutation analysis of three children with late-onset glycogen storage disease type II with hypertrophic cardiomyopathy]. Zhonghua Er Ke Za Zhi 2017; 55 (06) 423-427
  • 6 Park YE, Park KH, Lee CH, Kim CM, Kim DS. Two new missense mutations of GAA in late onset glycogen storage disease type II. J Neurol Sci 2006; 251 (1-2): 113-117
  • 7 Tsujino S, Huie M, Kanazawa N. et al. Frequent mutations in Japanese patients with acid maltase deficiency. Neuromuscul Disord 2000; 10 (08) 599-603
  • 8 Angelini C, Nascimbeni AC, Fanin M. Autophagy in natural history and after ERT in glycogenosis type II. JIMD Rep 2015; 21: 71-77
  • 9 Quan JJ, Liu LJ, Lyu TW, Huang XP, Tian J. Atypical infantile-onset Pompe disease with hypertrophic cardiomyopathy. Chin Med J (Engl) 2017; 130 (19) 2393-2394
  • 10 Pompe disease GAA variant database. Published 2019. Accessed July 2020 at: http://www.pompevariantdatabase.nl
  • 11 Nino MY, In 't Groen SLM, Bergsma AJ. et al. Extension of the Pompe mutation database by linking disease-associated variants to clinical severity. Hum Mutat 2019; 40 (11) 1954-1967
  • 12 Matsuishi T, Yoshino M, Terasawa K, Nonaka I. Childhood acid maltase deficiency. A clinical, biochemical, and morphologic study of three patients. Arch Neurol 1984; 41 (01) 47-52
  • 13 Nascimbeni AC, Fanin M, Tasca E, Angelini C. Molecular pathology and enzyme processing in various phenotypes of acid maltase deficiency. Neurology 2008; 70 (08) 617-626
  • 14 Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJ. The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 2012; 160C (01) 59-68
  • 15 Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr 2000; 137 (02) 283-285